Radiodynamic Therapy (RDT) With Gliolan in Patients With First Recurrence of Brain Tumor

The investigational drug 5-ALA (known under the trade name Gliolan®) is an approved drug for the surgical removal of malignant glioma (WHO grade III and IV). In this trial, the drug is being tested outside of its actual approval as a radiosensitizer in combination with conventional radiotherapy for first-time recurrence (relapse) of malignant glioma. In this clinical trial, the investigational drug 5-ALA is being used for the first time in a multiple dose escalation regimen in combination with radiotherapy following surgical removal of a recurrent malignant glioma in humans. The investigationa

Trial Details

NCT ID
NCT05590689
Phase
PHASE1 / PHASE2
Sponsor
Universität Münster
Status
RECRUITING
Cancer Type
Glioblastoma (GBM) Brain Cancer
Locations (sample)
  • Münster, Germany|51.96236,7.62571

Key Eligibility Criteria

  • Written patient consent after comprehensive information
  • Age \>/= 18 years
  • Recurrence of supratentorial glioblastoma after initial resection and adjuvant therapy (e.g. radio-chemotherapy, targeted therapies, antiangiogenic…
  • Clinically indicated further radiotherapy as per decision of the tumor board as part of therapy for recurrence

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Glioblastoma (GBM) Brain Cancer Trials on Trialify →